Efficacy and safety of immune checkpoint inhibitors in patients with neuroendocrine neoplasia: Report of a case series from a large tertiary centre

#3244

Introduction: Immune checkpoint inhibitors (ICI) have changed our view on how to treat cancer. Despite their approved treatment of many different cancers, efficacy of ICI in neuroendocrine neoplasia is limited and poorly understood. Established treatment options of neuroendocrine tumors (NET) and carcinomas (NEC) are based on surgery, tumor-targeted medical treatments, peptide guided radioreceptor therapy (PRRT) and locoregional therapies. However, in many patients these treatments lose efficacy over time, and novel therapies are urgently needed.

Aim(s): We aimed at identifying factors that might identify patients with neuroendocrine neoplasia with a particular benefit to checkpoint inhibitors.

Materials and methods: We analysed our database that comprises 612 patients with histologically proven diagnosis of NEN from 2008 to 2019 for cases of neuroendocrine tumors and carcinoma treated with immune checkpoint inhibitors. Eight patients could be identified. Clinical characteristics of these patients are systematically analysed and reported.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Özdirik B, Jann H, Tacke F, Wiedenmann B, Roderburg C,

Keywords: checkpoint inhibitor, neuroendocrine neoplasia, PD-L1,